Cardiac Biomarkers Market Segmentation Overview

The Cardiac Biomarkers Market involves the use of specific biological markers to assess heart function and diagnose cardiovascular diseases, such as myocardial infarction (heart attack), heart failure, and acute coronary syndrome. Cardiac biomarkers are measurable proteins or enzymes released into the bloodstream when the heart is under stress or damaged, offering crucial information for diagnosing, monitoring, and managing heart conditions. As cardiovascular diseases are among the leading causes of mortality worldwide, the demand for cardiac biomarkers has seen significant growth.

The global cardiac biomarkers market size reached USD 18.50 billion in 2023 and is predicted to surpass around USD 82.99 billion by 2034, growing at a solid CAGR of 14.62% over the forecast period 2024 to 2034

Cardiac Biomarkers Market Key Points

• North America dominated the cardiac biomarkers market with the largest market share of 41% in 2023.
• Asia Pacific is expected to grow at a double-digit CAGR of 16.02% during the forecasted years.
• By type, the troponin segment contributed the biggest market share of 34% in 2023.
• By type, the BNP and NT-proBNP segment is expected to grow at the fastest rate in the market over the forecast period.
• By application, the acute coronary syndrome segment accounted for the largest market share of 56% in 2023.
• By application, the other segment is expected to grow at a notable CAGR of 15.52% during the forecasted years.
• By end-use, the laboratory testing segment contributed the biggest market share of 68% in 2023.
• By end-use, the point-of-care testing segment is projected to expand at a solid CAGR of 14.93% during the forecasted years.

Download the Sample Report ( Including Full TOC, List of Table & Figures, Chart): https://www.precedenceresearch.com/sample/5065

By Type

1. Troponin

Troponin is considered the gold standard for diagnosing heart attacks (myocardial infarction). It is one of the most sensitive and specific markers for cardiac muscle damage. Troponin levels rise significantly within hours of a heart attack and can remain elevated for days, making it highly valuable for diagnosis.

• Market Share: Troponin dominates the cardiac biomarker market, accounting for more than 34% of the total market revenue in 2023.
• Growth Rate: The demand for troponin testing is expected to grow at a 7.5% CAGR over the next few years due to its widespread adoption in both hospital and outpatient settings.

2. CK-MB (Creatine Kinase-MB)

CK-MB is another widely used cardiac biomarker, though its usage has decreased as more sensitive markers like troponin became available. It is still used for early detection in myocardial infarction cases, especially when rapid results are needed.

• Market Share: Although CK-MB’s market share is declining, it still holds around 10-15% of the total market.
• Key Insight: CK-MB is often used in combination with troponin testing for a comprehensive diagnosis.

3. Myoglobin

Myoglobin is one of the earliest markers to rise after cardiac injury but lacks specificity as it can also increase with skeletal muscle damage. However, it is useful in emergency settings due to its fast response time.

• Market Share: Myoglobin constitutes approximately 5-10% of the market and is more commonly used in conjunction with other tests for faster diagnosis.

4. BNP and NT-proBNP (B-type Natriuretic Peptide)

BNP and NT-proBNP are primarily used for diagnosing and managing heart failure. These biomarkers are critical in determining the severity of heart failure and are also used in monitoring the effectiveness of treatments.

• Market Share: BNP and NT-proBNP contribute to about 20% of the cardiac biomarkers market, with a growing adoption rate due to the rise in cases of heart failure globally.
• Growth Rate: With heart failure cases increasing, this segment is expected to grow at a 6.9% CAGR.

5. Others

This segment includes biomarkers like C-reactive protein (CRP) and ischemia-modified albumin, which are gaining traction for their potential in identifying cardiac events and inflammation-related cardiovascular diseases.

• Market Share: The "Others" category occupies around 5% of the market, with room for growth as new biomarkers are researched and developed.

By Application

1. Acute Coronary Syndrome (ACS)

Acute coronary syndrome refers to a range of conditions, including unstable angina and myocardial infarction, that result from insufficient blood flow to the heart. Cardiac biomarkers are critical in diagnosing ACS, especially in emergency situations.

• Market Share: This application segment holds approximately 56% of the overall cardiac biomarker market, driven by the increasing incidence of ACS globally.
• Key Stat: In the U.S. alone, more than 1 million cases of ACS are reported annually, significantly driving demand for biomarker tests.

2. Myocardial Infarction (Heart Attack)

Myocardial infarction is one of the most common and critical conditions diagnosed using cardiac biomarkers. Troponin is the key biomarker used in this context, often combined with CK-MB and myoglobin for a comprehensive diagnosis.

• Market Share: This segment accounts for roughly 30% of the cardiac biomarkers market.
• Growth Rate: Due to the aging population and lifestyle factors like obesity and smoking, this segment is projected to grow at a 7% CAGR over the next five years.

3. Congestive Heart Failure (CHF)

Congestive heart failure is a condition where the heart is unable to pump blood effectively. Biomarkers like BNP and NT-proBNP play a crucial role in diagnosing and managing this condition, as they help assess the severity of heart failure and monitor treatment.

• Market Share: Congestive heart failure holds about 20-25% of the market share, largely due to the increasing global prevalence of heart failure cases.
• Key Stat: According to the World Health Organization, over 64 million people globally live with heart failure, boosting demand for cardiac biomarker tests.

4. Others

This segment includes other cardiovascular conditions where cardiac biomarkers may be used, such as arrhythmias, cardiomyopathies, and ischemic heart disease. The use of biomarkers in research for these conditions is still growing.

• Market Share: The "Others" category accounts for 5-10% of the market.

By End-use

1. Laboratory Testing

Laboratory testing remains the most common and reliable method for analyzing cardiac biomarkers. This segment includes large healthcare facilities and diagnostic laboratories that handle high volumes of biomarker tests daily.

• Market Share: Laboratory testing represents about 68% of the market, mainly due to the precision and accuracy offered by centralized labs.
• Key Insight: The demand for laboratory-based tests is growing as healthcare facilities invest in more sophisticated diagnostic technologies.

2. Point of Care Testing (POCT)

Point-of-care testing allows for rapid, near-patient diagnostic results, making it particularly useful in emergency departments and for outpatient care. As technology advances, POCT devices are becoming more popular in hospitals, clinics, and even home care settings.

• Market Share: POCT accounts for approximately 30% of the cardiac biomarkers market.
• Growth Rate: POCT is expected to grow at a 9% CAGR, driven by its convenience, faster diagnosis time, and increasing use in rural and underdeveloped areas where access to labs is limited.

Web: https://www.precedenceresearch.com/